Posted by Michael Wonder on 14 May 2020
China NMPA approves Optune for the treatment of newly diagnosed and recurrent glioblastoma
13 May 2020 - Optune is the first innovative treatment for glioblastoma approved in China in over 15 years.
Novocure and Zai Lab today announced that the China National Medical Products Administration has approved the marketing authorisation application for Optune in combination with temozolomide for the treatment of patients with newly diagnosed glioblastoma (GBM), and also as a monotherapy for the treatment of patients with recurrent GBM.
GBM is the most common form of primary brain cancer, and Optune is the first treatment for glioblastoma approved in China in over 15 years.
